Discontinued — last reported Q1 '26
Gardasil/Gardasil 9 — Sales
Merck & Co. Gardasil/Gardasil 9 — Sales decreased by 48.2% to $1.07B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 59.7%, from $2.65B to $1.07B. Over 4 years (FY 2021 to FY 2025), Gardasil/Gardasil 9 — Sales shows relatively stable performance with a -2.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful commercial execution, while a decrease may signal market saturation, competitive pressure, or supply chain constraints.
Detailed definition
This metric measures the total gross revenue generated from the global sale of the Gardasil and Gardasil 9 vaccine produ...
Peer comparison
Comparable to product-specific revenue reporting for major vaccine or specialty pharmaceutical franchises at peer global biopharmaceutical firms.
mrk_segment_gardasil_gardasil_9_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.47B | $3.99B | $3.06B | $2.92B | $3.35B | $4.59B | $2.94B | $3.94B | $4.92B | $5.17B | $3.74B | $4.50B | $4.96B | $4.61B | $3.10B | $2.65B | $2.25B | $3.50B | $2.06B | $1.07B |
| QoQ Change | — | +61.4% | -23.3% | -4.5% | +14.6% | +37.1% | -35.9% | +34.2% | +24.6% | +5.1% | -27.6% | +20.2% | +10.2% | -6.9% | -32.7% | -14.5% | -15.1% | +55.3% | -41.0% | -48.2% |
| YoY Change | — | — | — | — | +35.6% | +15.1% | -3.9% | +35.1% | +46.9% | +12.7% | +27.4% | +14.0% | +0.8% | -10.8% | -17.1% | -41.0% | -54.6% | -24.1% | -33.5% | -59.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s gardasil/gardasil 9 — sales?
- Merck & Co. (MRK) reported gardasil/gardasil 9 — sales of $1.07B in Q1 2026.
- How has Merck & Co.'s gardasil/gardasil 9 — sales changed year-over-year?
- Merck & Co.'s gardasil/gardasil 9 — sales decreased by 59.7% year-over-year, from $2.65B to $1.07B.
- What is the long-term trend for Merck & Co.'s gardasil/gardasil 9 — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s gardasil/gardasil 9 — sales has grown at a -2.0% compound annual growth rate (CAGR), from $11.35B to $10.47B.
- What does gardasil/gardasil 9 — sales mean?
- Total revenue generated from the sale of the Gardasil and Gardasil 9 vaccine product line.